Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, Lempicki R, Hengel RL, Sereti I, Lambert L, Dewar RL, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC.
Kovacs JA, et al. Among authors: baseler m.
Eur J Immunol. 2001 May;31(5):1351-60. doi: 10.1002/1521-4141(200105)31:5<1351::AID-IMMU1351>3.0.CO;2-9.
Eur J Immunol. 2001.
PMID: 11465092
Free article.
Clinical Trial.